SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Decipher Biosciences (formerly GenomeDx Inc.), a leader in the field of urologic cancer genomics, today announced that it will present results from seven studies featuring its Decipher® Prostate and Bladder Cancer Classifier Tests and Decipher Genomics Resource Information Database (Decipher GRID®). Results will be presented at the 2019 Genitourinary Cancers Symposium, which will be held February 14 – 16 at the Moscone Center in San Francisco.
Posters:
Title: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Abstract #42Presenter: Felix Y Feng, MD, University of California San Francisco, San Francisco, CA
Title: A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy. Abstract #8Presenter: Stephen J. Freedland, MD, Cedars-Sinai, Los Angeles, CA
Title: Genomic validation of three-tiered sub-classification of high-risk prostate cancer. Abstract #17Presenter: Vinayak Muralidhar, MD, MSc, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA
Title: Genomic biomarkers to predict outcome in Gleason Score 9-10 disease. Abstract #44Presenter: Amar Upadhyaya Kishan, MD, Ronald Reagan UCLA Medical Center, Santa Monica, CA
Title: Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of Decipher and PAM50 TESTS among different age groups. Abstract #38Presenter: Hanan Goldberg, MD, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
All posters presented Thursday, February 14: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM PST in Poster Session A: Prostate Cancer, Level 1, West Hall.
About Decipher Cancer Classifier Tests and GRIDDecipher Biosciences' prostate and bladder cancer classifiers are clinical, commercially available oncology tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher RP is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment.The Decipher tests are derived from Decipher Bioscience's Genomics Resource Information Database (GRID). GRID contains the genomic profiles of tens of thousands of tumors from patients with urological cancers, and is believed by Decipher Bioscience to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genomic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.Learn more at www.deciphertest.com and www.deciphergrid.com
About Decipher BiosciencesDecipher Biosciences is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. Decipher Biosciences is headquartered in San Diego, California.
Media Contact Joleen Schultz[email protected]
Advertisement
Posters:
Title: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Abstract #42Presenter: Felix Y Feng, MD, University of California San Francisco, San Francisco, CA
Advertisement
Title: A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy. Abstract #8Presenter: Stephen J. Freedland, MD, Cedars-Sinai, Los Angeles, CA
Title: Genomic validation of three-tiered sub-classification of high-risk prostate cancer. Abstract #17Presenter: Vinayak Muralidhar, MD, MSc, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA
Title: Genomic biomarkers to predict outcome in Gleason Score 9-10 disease. Abstract #44Presenter: Amar Upadhyaya Kishan, MD, Ronald Reagan UCLA Medical Center, Santa Monica, CA
Title: Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of Decipher and PAM50 TESTS among different age groups. Abstract #38Presenter: Hanan Goldberg, MD, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
All posters presented Thursday, February 14: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM PST in Poster Session A: Prostate Cancer, Level 1, West Hall.
About Decipher Cancer Classifier Tests and GRIDDecipher Biosciences' prostate and bladder cancer classifiers are clinical, commercially available oncology tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher RP is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment.The Decipher tests are derived from Decipher Bioscience's Genomics Resource Information Database (GRID). GRID contains the genomic profiles of tens of thousands of tumors from patients with urological cancers, and is believed by Decipher Bioscience to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genomic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.Learn more at www.deciphertest.com and www.deciphergrid.com
About Decipher BiosciencesDecipher Biosciences is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. Decipher Biosciences is headquartered in San Diego, California.
Media Contact Joleen Schultz[email protected]
View original content:http://www.prnewswire.com/news-releases/decipher-biosciences-announces-its-genomic-data-featured-at-2019-genitourinary-conference-in-multiple-prostate-cancer-presentations-300795519.html
SOURCE Decipher Biosciences
